- Clinical Technology
- Adult Immunization
- Hepatology
- Pediatric Immunization
- Screening
- Psychiatry
- Allergy
- Women's Health
- Cardiology
- Pediatrics
- Dermatology
- Endocrinology
- Pain Management
- Gastroenterology
- Infectious Disease
- Obesity Medicine
- Rheumatology
- Nephrology
- Neurology
- Pulmonology
FluMist Intranasal Flu Vaccine Now Available for At-Home Delivery and Self-Administration
AstraZeneca launches FluMist Home, the first FDA-approved at-home flu vaccine service, allowing self- or caregiver administration of the intranasal influenza vaccine for the 2025–26 season.
AstraZeneca has launched FluMist Home, the first at-home delivery service for an FDA-approved influenza vaccine that can be self-administered or given by a caregiver. The program expands access to FLUMIST® (Influenza Vaccine Live, Intranasal), the only nasal spray influenza vaccine available in the United States.
Under the approval, adults aged 18 to 49 years may self-administer FLUMIST, while parents or caregivers may administer it to children aged 2 to 17 years. First licensed in 2003, the vaccine is needle-free and delivered intranasally. With the 2025–2026 influenza season underway, individuals can now order the vaccine online, complete a medical screening, and, if eligible, receive it by mail with instructions for storage, administration, and disposal.
The initiative comes after the 2024–2025 influenza season was classified by the US Centers for Disease Control and Prevention as high severity across all age groups, with an estimated 610 000 hospitalizations and 27 000 deaths—the most severe flu season since the 2009 H1N1 pandemic.
A licensed health care provider will review all submissions made through the FluMist website to determine eligibility before prescriptions are dispensed. Vaccines will be shipped in temperature-controlled packaging by specialty pharmacy partners, and documentation of vaccination will be entered into state immunization information systems.
For the 2025–2026 season, FluMist Home will be available in 34 states, covering approximately 80% of the eligible US population. AstraZeneca noted that availability in some states is restricted by local pharmacy laws but expressed plans to expand to all 48 contiguous states in future seasons.
FLUMIST will remain available in traditional health care settings, including physician offices and pharmacies. The company emphasized that the home option is intended to improve convenience and potentially expand vaccination coverage, particularly among younger populations, where uptake has declined in recent years.
Source: FLUMIST® (Influenza, Vaccine Live, Intranasal), the nation’s only nasal spray flu vaccine, now available for home delivery. News release. August 15, 2025. Accessed August 18, 2025. https://www.astrazeneca-us.com/media/press-releases/2025/FLUMIST-the-nations-only-nasal-spray-flu-vaccine-now-available-for-home-delivery.html
